New hope for kidney transplant patients facing rejection
NCT ID NCT07006532
First seen Feb 19, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study tests whether adding the drug tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) can better control chronic active antibody-mediated rejection in kidney transplant recipients. About 50 participants with stable kidney function and certain biopsy results will be enrolled. The goal is to improve long-term kidney survival and reduce rejection-related damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Nooshin Dalili
RECRUITINGTehran, 1666663421, Iran
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.